Aclaris Therapeutics, Inc. (ACRS) Lowered to “Sell” at ValuEngine

ValuEngine lowered shares of Aclaris Therapeutics, Inc. (NASDAQ:ACRS) from a hold rating to a sell rating in a research report released on Tuesday.

A number of other brokerages have also recently commented on ACRS. Jefferies Group LLC reiterated a buy rating and issued a $36.00 target price on shares of Aclaris Therapeutics in a research report on Wednesday, June 28th. BidaskClub upgraded shares of Aclaris Therapeutics from a hold rating to a buy rating in a research report on Monday, July 24th. Cantor Fitzgerald set a $50.00 target price on shares of Aclaris Therapeutics and gave the stock a buy rating in a research report on Wednesday, August 9th. Guggenheim reiterated a buy rating and issued a $40.00 target price on shares of Aclaris Therapeutics in a research report on Tuesday, July 4th. Finally, JMP Securities reiterated an outperform rating and issued a $39.00 target price on shares of Aclaris Therapeutics in a research report on Friday, September 8th. Two analysts have rated the stock with a sell rating, one has given a hold rating and five have given a buy rating to the company’s stock. The stock currently has a consensus rating of Hold and an average target price of $40.00.

Shares of Aclaris Therapeutics (NASDAQ:ACRS) opened at 26.08 on Tuesday. Aclaris Therapeutics has a 52 week low of $20.15 and a 52 week high of $33.25. The company’s market cap is $697.27 million. The company has a 50 day moving average of $26.54 and a 200 day moving average of $27.80.

Aclaris Therapeutics (NASDAQ:ACRS) last posted its quarterly earnings data on Tuesday, August 8th. The biotechnology company reported ($0.56) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.68) by $0.12. On average, analysts expect that Aclaris Therapeutics will post ($3.10) EPS for the current year.

COPYRIGHT VIOLATION WARNING: “Aclaris Therapeutics, Inc. (ACRS) Lowered to “Sell” at ValuEngine” was posted by Ticker Report and is owned by of Ticker Report. If you are reading this piece on another publication, it was copied illegally and republished in violation of United States and international copyright & trademark legislation. The legal version of this piece can be viewed at https://www.tickerreport.com/banking-finance/2888436/aclaris-therapeutics-inc-acrs-lowered-to-sell-at-valuengine.html.

In other Aclaris Therapeutics news, Director Andrew N. Schiff bought 108,601 shares of the firm’s stock in a transaction that occurred on Wednesday, August 16th. The shares were bought at an average price of $23.02 per share, for a total transaction of $2,499,995.02. The purchase was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 16.30% of the stock is owned by company insiders.

Large investors have recently modified their holdings of the stock. Nationwide Fund Advisors grew its holdings in Aclaris Therapeutics by 8.3% in the 1st quarter. Nationwide Fund Advisors now owns 6,627 shares of the biotechnology company’s stock worth $198,000 after acquiring an additional 510 shares during the last quarter. American International Group Inc. grew its holdings in Aclaris Therapeutics by 31.3% in the 1st quarter. American International Group Inc. now owns 6,804 shares of the biotechnology company’s stock worth $203,000 after acquiring an additional 1,623 shares during the last quarter. UBS Group AG grew its holdings in Aclaris Therapeutics by 60.4% in the 1st quarter. UBS Group AG now owns 4,462 shares of the biotechnology company’s stock worth $133,000 after acquiring an additional 1,681 shares during the last quarter. Alps Advisors Inc. grew its holdings in Aclaris Therapeutics by 7.7% in the 2nd quarter. Alps Advisors Inc. now owns 24,129 shares of the biotechnology company’s stock worth $654,000 after acquiring an additional 1,718 shares during the last quarter. Finally, Alliancebernstein L.P. grew its holdings in Aclaris Therapeutics by 24.0% in the 1st quarter. Alliancebernstein L.P. now owns 9,300 shares of the biotechnology company’s stock worth $277,000 after acquiring an additional 1,800 shares during the last quarter. Institutional investors own 95.79% of the company’s stock.

About Aclaris Therapeutics

Aclaris Therapeutics, Inc is a dermatologist-led, biopharmaceutical company. The Company is focused on identifying, developing and commercializing differentiated drugs for the treatment of dermatological indications. The Company is also focused on the discovery and development of kinase inhibitors to treat inflammatory and immunological disorders and cancer.

Analyst Recommendations for Aclaris Therapeutics (NASDAQ:ACRS)

Receive News & Ratings for Aclaris Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aclaris Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

How to Trade on Forex – 8 Steps for Beginners
How to Trade on Forex – 8 Steps for Beginners
Super Nintendo World Theme Park Officially Starts Construction
Super Nintendo World Theme Park Officially Starts Construction
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Camera Zooms In and Can Recognize Faces
Camera Zooms In and Can Recognize Faces
Netflix Could See 150 Million Worldwide Subscribers
Netflix Could See 150 Million Worldwide Subscribers
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back


Leave a Reply

© 2006-2017 Ticker Report. Google+.